Eli Lilly Stock Tumbles on Slower-Than-Expected Weight Loss Drug Sales. Is This a Buying Opportunity?
Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...
NerdWallet12h
Best Brokerage Accounts for Online Stock Trading
In our analysis, these 12 brokerage accounts stand out as the best choices for stock trading, due to their low fees, strong platforms and quality customer support. Many, or all, of the products ...
S&P 500 Gains and Losses Today: Intel Stock Soars as Takeover Speculation Spreads
The S&P 500 jumped 1% on Friday, Jan. 17, 2025, heading into the long weekend on a high note as prospects rebounded for ...
Zacks.com on MSN17h
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...
Eli Lilly stock target cut, retains Buy rating on growth potential
Guggenheim analysts revised their price target for Eli Lilly (NYSE:LLY) shares, reducing it to $973.00 from the previous $995 ...
United Rentals price target lowered to $963 from $965 at Truist
Truist lowered the firm’s price target on United Rentals (URI) to $963 from $965 and keeps a Buy rating on the shares as part ...
Schlumberger Q4: Earnings Beat, Dividend Boost, Offshore Boom And More
Schlumberger reported better-than-expected Q4 2024 results, with revenue up 3%, EPS up 7%, and a 3% dividend increase.